Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Bonus Episode: Adequate mitomycin C can effectively reduce recurrence and progression in patients with IR NMIBC – the value of maintenance therapy*

15:49
 
Share
 

Manage episode 481398043 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.

Topics discussed include:

  • Current confusion about the clinical heterogeneity within the intermediate-risk patient group
  • The best way to select adequate intravesical therapy for this group
  • The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy

*References

  1. Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
  2. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
  3. Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
  4. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
  5. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
  6. Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.
  continue reading

200 episodes

Artwork
iconShare
 
Manage episode 481398043 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.

Topics discussed include:

  • Current confusion about the clinical heterogeneity within the intermediate-risk patient group
  • The best way to select adequate intravesical therapy for this group
  • The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy

*References

  1. Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
  2. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
  3. Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
  4. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
  5. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
  6. Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.
  continue reading

200 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play